Seventy-one adults with advanced STS who received 2 prior chemotherapeutics were randomized to selumetinib 75 mg p.o. bid and allowed to crossover upon progression , or to selumetinib 50 mg p.o. bid plus temsirolimus 20 mg i.v. weekly , with primary endpoint of progression-free survival ( PFS ) .